Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status.
de Bock
G H
GH
Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Mourits
M J E
MJ
Schutte
M
M
Krol-Warmerdam
E M M
EM
Seynaeve
C
C
Blom
J
J
Brekelmans
C T M
CT
Meijers-Heijboer
H
H
van Asperen
C J
CJ
Cornelisse
C J
CJ
Devilee
P
P
Tollenaar
R A E M
RA
Klijn
J G M
JG
D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016022:Case-Control Studies; D064447:Checkpoint Kinase 2; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D005838:Genotype; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D011960:Receptors, Estrogen / Q000378:metabolism*; D015996:Survival Rate
D011960:Receptors, Estrogen; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases